These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10891912)

  • 1. Effect of naratriptan on myocardial blood flow and coronary vasodilator reserve in migraineurs.
    Gnecchi-Ruscone T; Bernard X; Pierre P; Anderson D; Legg N; Enahoro H; Winter PD; Crisp A; Melin JA; Camici PG
    Neurology; 2000 Jul; 55(1):95-9. PubMed ID: 10891912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of subcutaneous naratriptan on forearm blood flow.
    Yogendran L; Boswell D; Nacci P; Winter P
    Cephalalgia; 1998 Sep; 18(7):476-80. PubMed ID: 9793700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sumatriptan and naratriptan tolerability and safety: an update of post-marketing experience.
    Welch KM
    Cephalalgia; 2001; 21 Suppl 1():25-8. PubMed ID: 11678818
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine.
    Bomhof M; Paz J; Legg N; Allen C; Vandormael K; Patel K
    Eur Neurol; 1999; 42(3):173-9. PubMed ID: 10529545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group.
    Havanka H; Dahlöf C; Pop PH; Diener HC; Winter P; Whitehouse H; Hassani H
    Clin Ther; 2000 Aug; 22(8):970-80. PubMed ID: 10972633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group.
    Mathew NT; Asgharnejad M; Peykamian M; Laurenza A
    Neurology; 1997 Dec; 49(6):1485-90. PubMed ID: 9409334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group.
    Klassen A; Elkind A; Asgharnejad M; Webster C; Laurenza A
    Headache; 1997; 37(10):640-5. PubMed ID: 9439085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Naratriptan Long-term Study Group.
    Bomhof MA; Heywood J; Pradalier A; Enahoro H; Winter P; Hassani H
    Cephalalgia; 1998 Jan; 18(1):33-7. PubMed ID: 9601622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials.
    Ashcroft DM; Millson D
    Pharmacoepidemiol Drug Saf; 2004 Feb; 13(2):73-82. PubMed ID: 14998068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naratriptan.
    Salonen R
    Int J Clin Pract; 1999; 53(7):552-6. PubMed ID: 10692743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naratriptan.
    Massiou H
    Curr Med Res Opin; 2001; 17 Suppl 1():s51-3. PubMed ID: 12463278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.
    Mannix LK; Savani N; Landy S; Valade D; Shackelford S; Ames MH; Jones MW
    Headache; 2007; 47(7):1037-49. PubMed ID: 17635595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Naratriptan Long-Term Study Group.
    Heywood J; Bomhof MA; Pradalier A; Thaventhiran L; Winter P; Hassani H
    Cephalalgia; 2000 Jun; 20(5):470-4. PubMed ID: 11037743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine.
    Garcia-Ramos G; MacGregor EA; Hilliard B; Bordini CA; Leston J; Hettiarachchi J
    Cephalalgia; 2003 Nov; 23(9):869-76. PubMed ID: 14616928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine.
    Brandes JL; Smith T; Diamond M; Ames MH
    Headache; 2007 Jun; 47(6):886-94. PubMed ID: 17578540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan.
    Stark S; Spierings EL; McNeal S; Putnam GP; Bolden-Watson CP; O'Quinn S
    Headache; 2000; 40(7):513-20. PubMed ID: 10940089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ergotamine on myocardial blood flow in migraineurs without evidence of atherosclerotic coronary artery disease.
    Gnecchi-Ruscone T; Lorenzoni R; Anderson D; Legg N; Tousoulis D; Winter PD; Crisp A; Camici PG
    Am J Cardiol; 1998 May; 81(9):1165-8. PubMed ID: 9605061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naratriptan: an alternative for migraine.
    Dulli DA
    Ann Pharmacother; 1999 Jun; 33(6):704-11. PubMed ID: 10410185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacy-clinic medication of the month. Naratriptan (naramig)].
    Scheen AJ
    Rev Med Liege; 1999 Mar; 54(3):189-91. PubMed ID: 10321110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of subcutaneous naratriptan on systemic and pulmonary haemodynamics and coronary artery diameter in humans.
    Hood S; Birnie D; Swan L; Murray LS; Whitehouse H; Winter P; Hillis WS
    J Cardiovasc Pharmacol; 1999 Jul; 34(1):89-94. PubMed ID: 10413073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.